Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Interview with Albert van der Zeijden
Read the interview with Albert van der Zeijden, Chair, Member of the PRAC, International Alliance of Patients Organisations.
Is social media changing the doctor – patient relationship?
At the moment, we do not see much change in the doctor – patient relationship through the use of social media. One reason may be that doctors do not have interest in it as long as there is no payment for time spent on social media. If it could play a role in enhancing communication between doctors and patients, it could be of importance. It could also be an accessible tool for patients to exchange information with other patients and to get reassurance in cases of mild health concerns.
How can we make communication between doctors and patients more effective?
The key is the decision making process, where patients need information and time for questions. This will be different for each patient as not all patients are on the same literacy level and the first consultation differs from follow-up consultations. Doctors have to listen to patients and patients have to be better prepared. The package leaflet could be used as a decision making aid if used in the consultation room. Currently, the patient gets the PL after the decision is made, which is too late. Also, here time is money and doctors should get remuneration for communication.
How can a better understanding be reached between the Pharma company and the customer?
The possibilities for a Pharma company to communicate directly with customers are very limited by legislation within the EU. Pharma companies cannot start practising their visions. Customers are again and again confronted with companies not living up to their own standards. Patient support programmes should be clearly informative and not promotional, which is not always the case. The relationship between patient organisations and companies must always be very transparent and it must be clear that financial support comes without influencing the policies of the P.O. This is particularly important if the members of the P.O. are patients who are potential users of a company's products.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.